BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BrainsWay expanded U.S. insurance coverage for Deep TMS treatment of OCD, bringing covered lives to more than 118 million. The company highlighted its position as the first to receive FDA clearance for a non-invasive brain stimulation OCD treatment and the only TMS company with published randomized, placebo-controlled pivotal data for the indication.
Key figures
- Covered lives
- over 118 million
- Fda cleared indications
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.